[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100282275":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":18,"centralContacts":23,"locations":28,"responsibleParty":46,"collaborators":10,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":10,"enrollmentInfo":58,"targetDuration":10,"studyType":61,"phases":10,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Sun Yat-sen University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"IgA nephropathy group",null,"Eligible biopsy-proven primary IgA nephropathy patients.",[13],"Other: No intervention",[15],{"type":6,"name":16,"description":16,"armGroupLabels":17,"otherNames":10},"No intervention",[9],[19],{"name":20,"affiliation":21,"role":22},"Xue Qing Yu, M.D. & Ph.D.","First Affiliated Hospital, Sun Yat-Sen University","PRINCIPAL_INVESTIGATOR",[24],{"name":20,"role":25,"phone":26,"phoneExt":10,"email":27},"CONTACT","8620-87766335","yuxq@mail.sysu.edu.cn",[29],{"facility":30,"status":31,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"The First Affiliated Hospital,Sun Yat-sen University","RECRUITING","Guangzhou","Guangdong","510080","China","CN",{"type":38,"coordinates":39},"Point",[40,41],113.25,23.11667,{"lat":41,"lon":40},[44],{"name":45,"role":25,"phone":26,"phoneExt":10,"email":27},"Xue Qing Yu, M.D.& Ph.D.",{"type":22,"investigatorFullName":47,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Xue Qing Yu","Professor","100282275","iga-nephropathy-biomarkers-evaluation-study-interest-100282275",false,"NCT02954419","IgA Nephropathy Biomarkers Evaluation Study (INTEREST)","INTEREST","Inclusion Criteria:\n\n* Male or female individuals aged 14 years or older\n* Patients with biopsy-proven primary IgA nephropathy\n* A renal biopsy available for reviewing must include 10 or more glomeruli.\n* The first renal biopsy was performed within 3 years.\n* eGFR ≥ 60 ml\u002Fmin\u002F1.73 m2 (MDRD formula);\n* Individuals or their legal representative who are able to understand and have voluntarily signed the informed consent form (ICF).\n\nExclusion Criteria:\n\n* Relatives were diagnosed with biopsy-proven primary IgA nephropathy;\n* Individuals had secondary IgA nephropathy due to diseases such as diabetes, chronic liver disease and systemic lupus erythematosus.","ALL","14 Years",{"count":59,"type":60},2000,"ESTIMATED","OBSERVATIONAL","This prospective cohort study is designed to examine the association between blood and urine biomarkers (including genetic variants) and long-term kidney disease progression among 2000 Chinese IgA nephropathy patients with relatively normal kidney function (eGFR≥60 ml\u002Fmin\u002F1.73 m2).",[64,65],"IgA Nephropathy","Glomerular Diseases",[64,67],"Biomarker","2026-04-08",{"date":70,"type":71},"2026-04-13","ACTUAL",{"date":73,"type":10},"2016-11",{"date":75,"type":60},"2027-01",{"name":5,"class":6},1]